Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Clindamycin × Thoracic × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Head & Neck 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Lung Neoplasms 1 Exanthema 1

Interventions

Carboplatin 505 Cisplatin 406 Pemetrexed 398 Radiotherapy 280 Docetaxel 244 Paclitaxel 226 pembrolizumab 225 Gemcitabine 197 Bevacizumab 190 Erlotinib Hydrochloride 189 Drug Therapy 186 Radiosurgery 174 Nivolumab 166 durvalumab 153 Etoposide 152 osimertinib 127 atezolizumab 108 Gefitinib 96 Blood Specimen Collection 92 Vinorelbine 90 Magnetic Resonance Spectroscopy 88 anlotinib 85 Surgical Procedures, Operative 85 Ipilimumab 61 Immunotherapy 61 Surveys and Questionnaires 59 sintilimab 58 Irinotecan 57 tislelizumab 56 Specimen Handling 56

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡